Retrophin's Focus Shifts After Phase III PKAN Drug's Failure
Fosmetpantotenate missed all endpoints in a Phase III trial, so Retrophin will shelve the candidate for the rare disease PKAN. Now, the biotech turns focus to Phase III sparsentan in a pair of indications.
You may also be interested in...
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.
Emerging Company Profile: CoA Therapeutics plans to start a Phase I study of a CoA modulator in the rare, genetic disorder PKAN during the first quarter of 2020.
The absurdity that's surrounded former drug company CEO Martin Shkreli, who has been indicted on eight federal charges, including securities fraud, has been made into a New York musical – really!